Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis
Physical Prehabilitation With and Without Creatine/Whey Protein Supplementation Effects on Frailty In Patients With Cirrhosis
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Confirmed diagnosis of cirrhosis by ICD-10 code, liver biopsy, abdominal imaging, or transient elastography * Access to digital device and internet at home * Ability to provide written informed consent before any study-related activities * Ability to remain in study for at least 3 months Exclusion Criteria: * Allergy to milk protein * On hemodialysis * No English language proficiency * Presence of condition or abnormality that in opinion of the Investigator will compromise safety of the patient or quality of the data * Concomitant severe underlying systemic illness that in the opinion of the Investigator would interfere with completion of study * Pregnant, breastfeeding, or intention of becoming pregnant during study time frame
About the study
Frailty and muscle health are important for patients with chronic liver disease. This study looks at the use of a digital prehabilitation app (HEAL-ME) plus creatine and whey protein combination supplementation on maintaining muscle health in patients with liver disease. The investigators anticipate that this combination of supplementation and nutrition/exercise prehabilitation app will maintain muscle health in patients with liver disease.
What is being tested
- HEAL-ME digital app (behavioral)
- Creatine supplementation (dietary supplement)
- Whey protein supplementation (dietary supplement)
- Placebo (dietary supplement)
Sponsor: University of California, San Francisco · Participants: 100 · Started: Apr 15, 2026
Contact the study team
- Melinda Wang, MD, MHS · Phone: 415-476-2777
Official record on ClinicalTrials.gov — NCT07029243
Locations in the U.S.
| California | University of California San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.